
Georgios A Christou

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5748159/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	The role of cardiac computed tomography in preâ€participation screening of mature athletes. European Journal of Sport Science, 2022, 22, 636-649.	2.7	0
2	Impact of a 246ÂKm ultraâ€marathon running race on heart: Insights from advanced deformation analysis. European Journal of Sport Science, 2022, 22, 1287-1295.	2.7	5
3	The minimizer Jaccard estimator is biased and inconsistent. Bioinformatics, 2022, 38, i169-i176.	4.1	12
4	OUP accepted manuscript. European Heart Journal Cardiovascular Imaging, 2022, , .	1.2	1
5	A critical review of the effects of vitamin K on glucose and lipid homeostasis: its potential role in the prevention and management of type 2 diabetes. Hormones, 2021, 20, 415-422.	1.9	14
6	Arterial Function after a 246 km Ultra-marathon Running Race. International Journal of Sports Medicine, 2021, 42, 1167-1173.	1.7	2
7	Exploring the Anthropometric, Cardiorespiratory, and Haematological Determinants of Marathon Performance. Frontiers in Physiology, 2021, 12, 693733.	2.8	3
8	High Tolerability of Pitavastatin Therapy: A Case Report of Comparison with other Statins. Cardiology, 2020, 145, 421-424.	1.4	2
9	Not only the status of body weight and metabolic health matters for cardiovascular events, but also the temporal changes. European Journal of Preventive Cardiology, 2020, , 2047487320937489.	1.8	3
10	Exploring the determinants of the cardiac changes after ultra-long duration exercise: The echocardiographic Spartathlon study. European Journal of Preventive Cardiology, 2020, 27, 1467-1477.	1.8	19
11	The regulation of serum resistin levels in metabolically healthy and unhealthy obese individuals. Hormones, 2020, 19, 523-529.	1.9	11
12	The impact of demographic, anthropometric and athletic characteristics on left atrial size in athletes. Clinical Cardiology, 2020, 43, 834-842.	1.8	6
13	The role of high density lipoprotein in the determination of the vascular effects of chronic exercise training in hypertensive patients. European Journal of Preventive Cardiology, 2019, 26, 1298-1300.	1.8	0
14	Indirect clinical markers for the detection of anabolic steroid abuse beyond the conventional doping control in athletes. European Journal of Sport Science, 2019, 19, 1276-1286.	2.7	8
15	Metabolically Healthy Obesity Is Characterized by a Proinflammatory Phenotype of Circulating Monocyte Subsets. Metabolic Syndrome and Related Disorders, 2019, 17, 259-265.	1.3	21
16	Semaglutide as a promising antiobesity drug. Obesity Reviews, 2019, 20, 805-815.	6.5	71
17	Pathophysiology of Noncardiac Syncope in Athletes. Sports Medicine, 2018, 48, 1561-1573.	6.5	7
18	The clinical significance of heart rate recovery as an estimate of dynamic hyperinflation and excess ventilation during exercise in chronic obstructive pulmonary disease. European Journal of Preventive Cardiology, 2018, 25, 1664-1666.	1.8	0

GEORGIOS A CHRISTOU

#	Article	IF	CITATIONS
19	Can Noncardiac Syncope Occur during Exercise?. Cardiology, 2017, 138, 159-163.	1.4	1
20	Serum fetuin-A levels are associated with serum triglycerides before and 6 months after bariatric surgery. Hormones, 2017, 16, 297-305.	1.9	8
21	Diagnosis and Treatment of Dyslipidaemias in Athletes. Current Vascular Pharmacology, 2017, 15, 238-247.	1.7	8
22	The relationship between retinol-binding protein 4 and apolipoprotein B-containing lipoproteins is attenuated in patients with very high serum triglycerides: A pilot study. Hormones, 2016, 15, 99-105.	1.9	1
23	Acute myocardial infarction in a young bodybuilder taking anabolic androgenic steroids: A case report and critical review of the literature. European Journal of Preventive Cardiology, 2016, 23, 1785-1796.	1.8	33
24	Pathophysiological mechanisms of noncardiac syncope in athletes. International Journal of Cardiology, 2016, 224, 20-26.	1.7	5
25	A novel strategy for evaluating tilt test in athletes with syncope. European Journal of Preventive Cardiology, 2016, 23, 1003-1010.	1.8	10
26	The Current Role of Liraglutide in the Pharmacotherapy of Obesity. Current Vascular Pharmacology, 2016, 14, 201-207.	1.7	18
27	The relationship between retinol-binding protein 4 and apolipoprotein B-containing lipoproteins is attenuated in patients with very high serum triglycerides: A pilot study. Hormones, 2016, 15, 99-105.	1.9	2
28	Editorial: Liraglutide and Cardiometabolic Effects: More than Just Another Antiobesity Drug?. Current Vascular Pharmacology, 2015, 14, 76-79.	1.7	7
29	The Current Role of Omega-3 Fatty Acids in the Management of Atrial Fibrillation. International Journal of Molecular Sciences, 2015, 16, 22870-22887.	4.1	16
30	The efficacy and safety of the naltrexone/bupropion combination for the treatment of obesity: an update. Hormones, 2015, 14, 370-5.	1.9	11
31	The role of adiponectin in renal physiology and development of albuminuria. Journal of Endocrinology, 2014, 221, R49-R61.	2.6	68
32	Confronting the Residual Cardiovascular Risk Beyond Statins: The Role of Fibrates, Omega-3 Fatty Acids, or Niacin, in Diabetic Patients. Current Pharmaceutical Design, 2014, 20, 3675-3688.	1.9	3
33	The Changes in Plasma Retinol-Binding Protein 4 Levels are Associated With Those of the Apolipoprotein B-Containing Lipoproteins During Dietary and Drug Treatment. Angiology, 2012, 63, 67-75.	1.8	16
34	High density lipoprotein is positively correlated with the changes in circulating total adiponectin and high molecular weight adiponectin during dietary and fenofibrate treatment. Hormones, 2012, 11, 178-188.	1.9	18